Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-α

Journal of Interferon and Cytokine Research

Volumn 24, Issue 10, 2004, Pages 585-593

  Luik, Armin ^a   Knapp, Susanne ^b   Thursz, Mark ^b   Thomas, Howard C ^b   Schlaak, Jörg F ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; INTERLEUKIN 10;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

HEPATITIS C VIRUS;

EID: 4944222054     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2004.24.585     Document Type: Article

References (49)

1. LIANG, T.J., REHERMANN, B., SEEFF, L.B., and HOOFNAGLE, J. H. (2000). Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296-305.
2. LINDSAY, K.L., TREPO, C., HEINTGES, T., SHIFFMAN, M.L., GORDON, S.C., HOEFS, J.C., SCHIFF, E.R., GOODMAN, Z.D., LAUGHLIN, M., YAO, R., and ALBRECHT, J.K. (2001). A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395-403.
3. REDDY, K.R., WRIGHT, T.L., POCKROS, P.J., SHIFFMAN, M., EVERSON, G., REINDOLLAR, R., FRIED, M.W., PURDUM, P.P., III, JENSEN, D., SMITH, C., LEE, W.M., BOYER, T.D., LIN, A., PEDDER, S., and DEPAMPHILIS, J. (2001). Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33, 433-438.
4. GLUE, P., ROUZIER-PANIS, R., RAFFANEL, C., SABO, R., GUPTA, S.K., SALFI, M., JACOBS, S., and CLEMENT, R.P. (2000). A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32, 647-653.
5. ISAACS, A., and LINDENMANN, J. (1957). Virus interference. I. The interferon. Proc. R. Soc. London Ser. B 147, 258-267.
6. KUMAR, R., and ATLAS, I. (1992). Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc. Natl. Acad. Sci. USA 89, 6599-6603.
7. MELAMED, D., TIEFENBRUN, N., YARDEN, A., and KIMCHI, A. (1993). Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells. Mol. Cell. Biol. 13, 5255-5265.
8. UZE, G., LUTFALLA, G., and MOGENSEN, K.E. (1995). Alpha and beta interferons and their receptor and their friends and relations. J. Interferon Cytokine Res. 15, 3-26.
9. TANIGUCHI, T., and TAKAOKA, A. (2001). A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2, 378-386.
10. (+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13, 643-655.
11. BIRON, C.A., NGUYEN. K.B., PIEN, G.C., COUSENS, L.P., and SALAZAR-MATHER, T.P. (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220.
12. PARRONCHI, P., MOHAPATRA, S., SAMPOGNARO, S., GIANNARINI, L., WAHN, U., CHONG, P., MAGGI, E., RENZ, H., and ROMAGNANI, S. (1996). Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur. J. Immunol. 26, 697-703.
13. PESTKA, S. (2000). The human interferon alpha species and receptors. Biopolymers 55, 254-287.
14. STARK, G.R., KERR, I.M., WILLIAMS, B.R., SILVERMAN, R.H., and SCHREIBER, R.D. (1998). How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264.
15. DARNELL, J.E., Jr., KERR, I.M., and STARK, G.R. (1994). Jak-Stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
16. ICHIKAWA, T., NAKAO, K., NAKATA, K., YAMASHITA, M., HAMASAKI, K., SHIGENO, M., ABIRU, S., ISHIKAWA, H., ISHII, N., and EGUCHI, K. (2002). Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. Biochem. Biophys. Res. Commun. 294, 414-422.
17. ITO, S., ANSARI, P., SAKATSUME, M., DICKENSHEETS, H., VAZQUEZ, N., DONNELLY, R. P., LARNER, A. C., and FINBLOOM, D. S. (1999). Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of Stat1. Blood 93, 1456-1463.
18. TIAN, Z., SHEN, X., FENG, H., and GAO, B. (2000). IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and Stat1 activation in the liver: involvement of proteasome-dependent pathway. J. Immunol. 165, 3959-3965.
19. BASU, A., MEYER, K., RAY, R.B., and RAY, R. (2001). Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 288, 379-390.
20. HEIM, M.H., MORADPOUR, D., and BLUM, H.E. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-Stat pathway. J. Virol. 73, 8469-8475.
21. LOEHR, H.F., GERKEN, G., ROTH, M., WEYER, S., SCHLAAK, J.F., and MEYER ZUM BUESCHENFELDE, K.H. (1998). The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. J. Hepatol. 29, 524-532.
22. + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 21, 632-638.
23. ALTER, H.J. (1992). New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 15, 350-353.
24. DIEPOLDER, H.M., ZACHOVAL, R., HOFFMANN, R.M., WIERENGA, E.A., SANTANTONIO, T., JUNG, M.C., EICHENLAUB, D., and PAPE, G.R. (1995). Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346, 1006-1007.
25. SIMMONDS, P., HOLMES, E.C., CHA, T.A., CHAN, S.W., McOMISH, F., IRVINE, B., BEALL, E., YAP, P.L., KOLBERG, J., and URDEA, M.S. (1993). Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74, 2391-2399.
26. SCHLAAK, J.F., LOEHR, H.F., GALLATI, H., MEYER ZUM BUESCHENFELDE, K.H., and FLEISCHER, B. (1993). Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin. Exp. Immunol. 94, 168-173.
27. SCHLAAK, J.F., PITZ, T., LOEHR, H.F., MEYER ZUM BUESCHENFELDE, K.H., and GERKEN, G. (1998). Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. J. Med. Virol, 56, 112-117.
28. GERMER, S., HOLLAND, M.J., and HIGUCHI, R. (2000). High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res. 10, 258-266.
29. NELSON, D.R., LAUWERS, G.Y., LAU, J.Y., and DAVIS, G.L. (2000). Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118, 655-660.
30. McHUTCHISON, J.G., GIANNELLI, G., NYBERG, L., BLATT, L.M., WAITE, K., MISCHKOT, P., PIANKO, S., CONRAD, A., and GRINT, P. (1999). A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J. Interferon Cytokine Res. 19, 1265-1270.
31. BARNES, E., HARCOURT, G., BROWN, D., LUCAS, M., PHILLIPS, R., DUSHEIKO, G., and KLENERMAN, P. (2002). The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36, 743-754.
32. ALVARADO, E.C., ELEWAUT, A., PHILIPPE, J., ELEWAUT, A.E., DESOMBERE, I., MAERTENS, G., and LEROUX-ROELS, G. (2002). Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha. Rev. Invest. Clin. 54, 41-50.
33. VERTUANI, S., BAZZARO, M., GUALANDI, G., MICHELETTI, F., MARASTONI, M., FORTINI, C., CANELLA, A., MARINO, M., TOMATIS, R., TRANIELLO, S., and GAVIOLI, R. (2002). Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 32, 144-154.
34. CRAMP, M.E., ROSSOL, S., CHOKSHI, S., CARUCCI, P., WILLIAMS, R., and NAOUMOV, N.V. (2000). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118, 346-355.
35. + T cells (H9). Eur. Cytokine Netw. 12, 69-77.
36. PAYVANDI, F., AMRUTE, S., and FITZGERALD-BOCARSLY, P. (1998). Exogenous and endogenous IL-10 regulate IFN-alpha production by peripheral blood mononuclear cells in response to viral stimulation. J. Immunol. 160, 5861-5868.
37. ZHAO, X.X., LIAO, M.J., and RASHIDBAIGI, A. (1998). Inhibitory effect of interleukin-10 on human leukocyte interferon-alpha production by Sendai virus. Cytokines Cell Mol. Ther. 4, 11-16.
38. SHEN, X., HONG, F., NGUYEN, V.A., and GAO, B. (2000). IL-10 attenuates IFN-alpha-activated Stat1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. 480, 132-136.
39. NEUMANN, A.U., LAM, N.P., DAHARI, H., GRETCH, D.R., WILEY, T.E., LAYDEN, T.J., and PERELSON, A.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107.
40. NAKAMUTA, M., FUKUTOMI, T., SHIMOHASHI, N., KINUKAWA, N., UCHIMURA, K., TADA, S., MOTOMURA, K., ENJOJI, M., KATO, M., IWAMOTO, H., TANABE, Y., IMARI, Y., SAKAMOTO, S., SAKAI, H., and NAWATA, H. (2001). Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response. J. Gastroenterol. Hepatol. 16, 29-33.
41. FUKUTOMI, T., NAKAMUTA, M., FUKUTOMI, M., IWAO, M., WATANABE, H., HIROSHIGE, K., TANABE, Y., and NAWATA, H. (2001). Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J. Hepatol. 34, 100-107.
42. ZEUZEM, S., HERRMANN, E., LEE, J.H., FRICKE, J., NEUMANN, A.U., MODI, M., COLUCCI, G., and ROTH, W.K. (2001). Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 120, 1438-1447.
43. ROSEN, H.R., RIBEIRO, R.R., WEINBERGER, L., WOLF, S., CHUNG, M., GRETCH, D.R., and PERELSON, A.S. (2002). Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J. Hepatol. 37, 124-130.
44. LAYDEN, T.J., MIKA, B., and WILEY, T.E. (2000). Hepatitis C kinetics: mathematical modeling of viral response to therapy. Semin. Liver Dis. 20, 173-183.
45. KUZUSHITA, N., HAYASHI, N., KATAYAMA, K., KANTO, T., OSHITA, M., HAGIWARA, H., KASAHARA, A., FUSAMOTO, H., and KAMADA. T. (1997). High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand. J. Gastroenterol. 32, 169-174.
46. EDWARDS-SMITH, C.J., JONSSON, J.R., PURDIE, D.M., BANSAL, A., SHORTHOUSE, C., and POWELL, E.E. (1999). Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30, 526-530.
47. KNAPP, S., HENNIG, B.J.W., FRODSHAM, A.J., ZHANG, L., HELLIER, S., WRIGHT, M., GOLDIN, R., HILL, A.V.S., THOMAS, H.C., and THURSZ, M.R. (2003). Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55, 362-369.
48. YEE, L.J., TANG, J., GIBSON, A.W., KIMBERLY, R., VAN LEEUWEN, D.J., and KASLOW, R.A. (2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33, 708-712.
49. VIDIGAL, P.G., GERMER, J.J., and ZEIN, N.N. (2002). Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J. Hepatol. 36, 271-277.